iPSC-Derived Cardiomyocyte Therapy for Heart Failure from United States
iPSC-derived cardiomyocyte therapy involves induced pluripotent stem cells differentiated into cardiomyocytes for intramyocardial injection to repair heart tissue after myocardial infarction. These engineered cell cultures are classified under tariff item 3002.51.00 as cell therapy products.
Duty Rate — United States → Canada
0%
Import Tips
• Document the differentiation process from iPSCs to cardiomyocytes to support classification under 3002.51.00
• Verify that the product is not classified as a pharmaceutical under heading 30.04
• Ensure compliance with Canadian regulations for stem cell therapies